Quantbot Technologies LP Acquires Shares of 226,274 Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Quantbot Technologies LP purchased a new position in Teva Pharmaceutical Industries Limited (NYSE:TEVA - Free Report) during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm purchased 226,274 shares of the company's stock, valued at approximately $4,987,000.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Stifel Financial Corp boosted its stake in shares of Teva Pharmaceutical Industries by 54.0% in the 3rd quarter. Stifel Financial Corp now owns 66,391 shares of the company's stock worth $1,196,000 after buying an additional 23,283 shares during the last quarter. Robeco Institutional Asset Management B.V. boosted its stake in shares of Teva Pharmaceutical Industries by 7.2% in the 4th quarter. Robeco Institutional Asset Management B.V. now owns 498,309 shares of the company's stock worth $10,983,000 after buying an additional 33,277 shares during the last quarter. Thrivent Financial for Lutherans boosted its stake in shares of Teva Pharmaceutical Industries by 21.8% in the 3rd quarter. Thrivent Financial for Lutherans now owns 224,511 shares of the company's stock worth $4,046,000 after buying an additional 40,218 shares during the last quarter. Sio Capital Management LLC purchased a new position in shares of Teva Pharmaceutical Industries in the 3rd quarter worth $24,314,000. Finally, Pinnbrook Capital Management LP purchased a new position in Teva Pharmaceutical Industries during the fourth quarter valued at $4,966,000. 54.05% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling

In related news, Director Roberto Mignone sold 286,000 shares of the business's stock in a transaction dated Friday, December 20th. The stock was sold at an average price of $22.01, for a total value of $6,294,860.00. Following the sale, the director now directly owns 695,000 shares in the company, valued at approximately $15,296,950. The trade was a 29.15 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 0.55% of the stock is owned by company insiders.

Remove Ads

Teva Pharmaceutical Industries Price Performance

Shares of Teva Pharmaceutical Industries stock traded down $0.24 during trading hours on Tuesday, hitting $16.48. The company's stock had a trading volume of 9,443,030 shares, compared to its average volume of 9,403,697. The business has a 50 day moving average price of $18.09 and a two-hundred day moving average price of $18.26. Teva Pharmaceutical Industries Limited has a 12-month low of $12.51 and a 12-month high of $22.80. The company has a market cap of $18.68 billion, a PE ratio of -11.36, a PEG ratio of 1.44 and a beta of 0.82. The company has a debt-to-equity ratio of 2.97, a quick ratio of 0.75 and a current ratio of 0.98.

Teva Pharmaceutical Industries (NYSE:TEVA - Get Free Report) last posted its earnings results on Wednesday, January 29th. The company reported $0.70 EPS for the quarter, topping analysts' consensus estimates of $0.69 by $0.01. Teva Pharmaceutical Industries had a positive return on equity of 42.46% and a negative net margin of 9.91%. Analysts expect that Teva Pharmaceutical Industries Limited will post 2.5 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several research firms have issued reports on TEVA. Bank of America cut their price target on Teva Pharmaceutical Industries from $23.00 to $20.00 and set a "buy" rating for the company in a report on Thursday, March 6th. UBS Group cut their price target on Teva Pharmaceutical Industries from $30.00 to $27.00 and set a "buy" rating for the company in a report on Thursday, January 30th. Barclays cut their price target on Teva Pharmaceutical Industries from $28.00 to $26.00 and set an "overweight" rating for the company in a report on Thursday, January 30th. Piper Sandler boosted their price target on Teva Pharmaceutical Industries from $23.00 to $30.00 and gave the company an "overweight" rating in a report on Friday, January 17th. Finally, StockNews.com lowered Teva Pharmaceutical Industries from a "buy" rating to a "hold" rating in a report on Friday, March 7th. Two research analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. According to data from MarketBeat, Teva Pharmaceutical Industries currently has an average rating of "Moderate Buy" and a consensus price target of $23.43.

Teva Pharmaceutical Industries Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.